(VIANEWS) – VISTIN PHARMA (VISTN.OL) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| VISTIN PHARMA (VISTN.OL) | kr24.30 | 3.13% | 16.03% |
| LNA SANTE (LNA.PA) | €19.20 | 2.54% | 9.08% |
| EUROFINS SCIENT. (ERF.PA) | €56.78 | 2.16% | 9.12% |
| EQUASENS (EQS.PA) | €56.70 | 1.88% | 27.25% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. VISTIN PHARMA (VISTN.OL)
3.13% Forward Dividend Yield and 16.03% Return On Equity
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, produces and sells active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, VISTIN PHARMA has a trailing twelve months EPS of kr1.
PE Ratio
VISTIN PHARMA has a trailing twelve months price to earnings ratio of 24.3. Meaning, the purchaser of the share is investing kr24.3 for every norwegian krone of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.03%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.8%, now sitting on 438.54M for the twelve trailing months.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jan 23, 2024, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 3.13%.
More news about VISTIN PHARMA.
2. LNA SANTE (LNA.PA)
2.54% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, surgery, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.28.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 8.42. Meaning, the purchaser of the share is investing €8.42 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 732.02M for the twelve trailing months.
Yearly Top and Bottom Value
LNA SANTE’s stock is valued at €19.20 at 11:30 EST, way under its 52-week high of €34.00 and above its 52-week low of €19.00.
More news about LNA SANTE.
3. EUROFINS SCIENT. (ERF.PA)
2.16% Forward Dividend Yield and 9.12% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €2.28.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 24.9. Meaning, the purchaser of the share is investing €24.9 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.12%.
Yearly Top and Bottom Value
EUROFINS SCIENT.’s stock is valued at €56.78 at 11:30 EST, way under its 52-week high of €72.64 and way higher than its 52-week low of €44.83.
Moving Average
EUROFINS SCIENT.’s value is higher than its 50-day moving average of €52.99 and under its 200-day moving average of €59.57.
Revenue Growth
Year-on-year quarterly revenue growth declined by 5.9%, now sitting on 6.51B for the twelve trailing months.
More news about EUROFINS SCIENT..
4. EQUASENS (EQS.PA)
1.88% Forward Dividend Yield and 27.25% Return On Equity
Equasens Société anonyme provides healthcare IT solutions in Europe. It offers id. PATIENT, a business software; id. MOBILITY, a back-office management software; pandaLAB Pro, an instant messaging solution; Id. VENTE, an HAS-certified drug database; Id. COMMANDE, an order management module; dispensing robots; Services Ségur id; id. DOSAGE, a dosage management and printing module; multimeds reconditioning robot; compliance monitoring module; home delivery module; home equipment rental management module; Visiodroits module; and Website connector. The company also provides id. DESK, an informative and interactive dashboard; id. UP!, a real-time monitoring and control application of id management software; id. EASYQ, a queue management solution; Miaterapia; Id. SHOW, an application for managing real-time communications on pharmacy screens; Pharmaweb; TsGatePro; LMO, a dispensary business software; and LGO, a dispensary management software. In addition, it offers DOMILINK HAD software; mobiSOINS mobility tool; MEMORialis, support software for alzheimer's monitoring teams; HOSPILINK, an hospital information system applications; HOSPILINK DPI, a computerized patient file; HOSPILINK LOOKUP Big Data; eNephro solutions; NOVIAcare solutions; KAP&LINK2, a contact chip card reader terminal and NFC reader; eS-KAP-Ad, a connected nomadic tool incorporating software; KAP-INSIDE, a mobile terminal; and TI-KAP allowing access to contact and contactless cards. Further, the company provides AUTHENTICATOR, a patented authentication system; KAP'TEUR by KAPELSE, a patented universal sensor; ExpressVitale; MédiStory, that automates the transfer of invoicing to the healthcare professional's accounting. Additionally, it offers medical telesecretarial services for healthcare professionals, as well as equipment lease financing solutions. The company was incorporated in 1996 and is headquartered in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 18.59. Meaning, the purchaser of the share is investing €18.59 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 27.25%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, EQUASENS’s stock is considered to be overbought (>=80).
Volume
Today’s last reported volume for EQUASENS is 1366 which is 82.22% below its average volume of 7687.
More news about EQUASENS.
